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Abstract
Introduction Given the pivotal role of T lymphocytes in the
immune system, patients with septic shock may show T cell
abnormalities. We have characterised the T cell compartment in
septic shock and assess its clinical implications.
Methods T lymphocytes from the peripheral blood of 52
patients with septic shock and 36 healthy control subjects were
analysed on admission to the intensive care unit, baseline, and
3, 7, 14 and 28 days later. T cell phenotypes (CD3+CD4+/
CD3+CD8+, CD45RA+/CD45RO+, CD62L+/CD28+) were
assessed by quantitative flow cytometry.
Results CD3+, CD3+CD4+ and CD3+CD8+ lymphocyte
counts were significantly lower in patients with septic shock
than control subjects. In surviving patients, CD3+CD4+
lymphocytes had normalised after 14 days, yet CD3+CD8+
numbers were still low. Non effector CD45RA+CD45RO-
subsets of CD3+CD4+ and CD3+CD8+ were persistently low
during patient follow up. CD3+CD8+CD28+ and
CD3+CD8+CD62L+ were reduced in patients versus controls
and survivors versus nonsurvivors in the first three days. A
prediction receptor operative curve revealed that for the
CD3+CD8+CD28+ subset, a cutoff of 136 cells/ml showed
70% sensitivity and 100% specificity for predicting death and
the area under the curve was 0.84 at admission. Corresponding
values for CD3+CD8+CD62L+ were 141 cells/ml, 60%
sensitivity, 100% specificity and an area under the curve of
0.75.
Conclusions A severe redistribution of T lymphocyte subsets is
found in septic shock patients. A different kinetic pattern of T
cell subset involvement is observed in surviving and
nonsurviving patients, with lower numbers of circulating
CD3+CD8+CD28+ and CD3+CD8+CD62L+ associated with
a better disease outcome.
Introduction
Sepsis has been defined as the systemic inflammatory
response syndrome that occurs in response to bacterial infec-
tion [1]. Although the pathogenesis of sepsis is complex, cur-
rent evidence points to a direct triggering effect of bacteria
and, in greater measure, to an abnormal systemic immune
response [2-4].
The T cell compartment plays a pivotal role in regulating the
effector stage of the immune response. CD3+CD4+ T cells
are mainly involved in the regulation of the immune response,
and CD3+CD8+ T cells are critical in the cytotoxic response
[5]. Several molecules, mainly the T cell receptor/CD3 com-
plex and other co-receptors including CD28, contribute to the
activation of T lymphocytes. The expression patterns of other
molecules, such as the CD45 isoforms RA and RO, vary dur-
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ing the different T cell activation effector stages [6]. Activated
T lymphocytes show several profiles (proinflammatory or anti-
inflammatory) of cytokine production [7]. Other molecules,
such as CD62L, participate in the immune response by regu-
lating the tissue distribution of the T lymphocytes.
A role for T lymphocytes in severe systemic bacterial infections
has been described in several studies [13-16] , and the find-
ings of other investigations have supported the notion that T
lymphocytes are involved in the pathogenesis of septic shock
[8-12]. In this translational study, we have further character-
ised the abnormalities of the T cell compartment in septic
shock and explore its clinical significance. During the first 28
days of follow up circulating T lymphocytes of 52 patients with
septic shock admitted to the intensive care unit (ICU) were
analysed and 36 healthy subjects were analysed in parallel.
We determined the counts and distributions of the main T cell
subsets, as well as their stage of activation (CD3, CD4, CD8,
CD28, 45RA, 45RO and 62L antigens).
Materials and methods
Patients
Fifty-two consecutive patients admitted to the ICU of the Uni-
versity Hospital Príncipe de Asturias, Madrid, Spain, with sep-
tic shock, diagnosed according to the criteria of the American
College of Chest Physicians/Society of Critical Care Medicine
[13], were enrolled in the study. A further requirement was the
demonstration of an infectious aetiology through microbiologi-
cal (Gram stain and/or culture) and/or radiological techniques,
or direct observation of the infection focus. The study protocol
did not call for a standardised approach to critical care. Exclu-
sion criteria were: anything causing primary or acquired immu-
nodeficiency, previous immunosuppressive or
immunomodulation treatment, cancer, or autoimmune or aller-
gic disease. The study was conducted according to the guide-
lines of the 1975 Declaration of Helsinki, after obtaining the
Hospital Universitario Príncipe de Asturias Ethics Committee
approval. Written informed consent was obtained from each
subject included in the study or surrogate legal representa-
tives.
Thirty-six age-matched and sex-matched healthy blood donors
were studied in parallel with the patients (0 and 28 days of the
follow up). They were studied to control the adequacy of the
cytometric techniques as well as to characterise the normal
range of the T lymphocyte compartment parameters analysed.
Study design
Blood was collected from the patients at baseline (ICU admis-
sion) and at 3, 7, 14 and 28 days of follow up, and at baseline
and at 28 days in healthy controls. White blood cell differential
counts were conducted in a COULTER® LH instrument (Beck-
man-Coulter Inc, Fullerton, CA, USA).
Cell separation and in vitro culture
Peripheral blood mononuclear cells (PBMC) were obtained
from heparinised venous blood by Ficoll-Hypaque (Lympho-
prep Nyegaard, Oslo, Norway) density gradient centrifugation.
Cells were resuspended (1 × 106 cells/ml) in RPMI-1640
(Biowhittaker Inc, Walkersville, MD, USA) supplemented with
10% heat-inactivated FBS (Cangera International, Ontario,
Canada), 25 mM Hepes (Biochrom KG, Berlin, Germany) and
1% penicillin streptomycin (Difco Lab, Detroit, MI, USA).
Surface immunofluorescence and T cell numbers
T cells were phenotypically analysed in PBMC by four-colour
flow cytometry in a FACScalibur cytometer using CellQuest-
3.3 software (Becton-Dickinson, San Jose, CA, USA). PBMC
were incubated with combinations of fluorescein isothiocy-
anate (FITC), phycoerythrin (PE), phycoerythrin-cyanine 5.5
(PE-cy5.5), peridinin chlorophyll protein (PerCP) and allophy-
cocyanin (APC)-labelled monoclonal antibodies. The mono-
clonal antibodies were CD3-PerCP, CD3-FITC, CD45RA
FITC, CD56-PE, CD28-PE, CD62L-PE (Becton-Dickinson,
San Jose, CA, USA), CD19-PE-CY5, CD8-APC, CD45RO PE
(Caltag Laboratories, San Francisco, CA, USA).
Absolute number lymphocytes calculation
The absolute numbers of T lymphocyte subsets were calcu-
lated according to standard flow cytometry criteria for lym-
phocyte subset identification and the lymphocytes obtained in
conventional haemogram. First, we calculated the percentage
of cells expressing CD3 in the total lymphocytes gate defined
by forward and side scatter in PBMC. The absolute number of
circulatory T lymphocytes was calculated by the percentage of
CD3+ cells in peripheral blood lymphocytes multiplied by the
total number of lymphocytes per microlitre measured by a
Coulter®. Next, we obtained the absolute number of CD4+
and CD8+ T lymphocytes by multiplying the total number of T
lymphocytes previously calculated by the percentage of posi-
tive cells for each one of both antigens in CD3+ T cells. We
simultaneously stained PBMC with CD3, CD4 and CD8 anti-
bodies to obtain this data. Finally, we calculated the absolute
number of the CD3+CD4+ and CD3+CD8+ T cells subsets
defined by the expression of CD45 isoforms
CD45RA+CD45RO-, CD45RO+CD45RA-,
CD45RA+CD45RO+ and the expression of the antigens
CD28+ and CD62L+. To calculate these numbers, we multi-
plied the percentage obtained of each subset in the parents'
CD3+CD4+ or CD3+CD8+ populations by the absolute
count of CD3+CD4+ and CD3+CD8+ T cells, respectively.
All absolute numbers are expressed as cells/ml.
Statistical analysis
Analyses were performed using SPSS-11.0 software (SPSS,
Chicago, IL, USA). Most variables did not fulfill the normality
hypothesis, so the Mann Whitney U-test for non-parametric
data was used to analyse differences between the groups, and
analysis of variance followed by Wilcoxon Signed Ranks testsAvailable online http://ccforum.com/content/13/1/R26
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were used for within group analyses. The level of significance
was set at P < 0.05.
Results
Patients
There were ninety-two ICU admissions with a diagnosis of
septic shock during the study period. Forty patients were
excluded from the study: three patients were HIV-positive, 18
patients were taking corticosteroids on admission, 12 were on
or had received chemotherapy, five patients suffered neopla-
sia, one had rheumatoid arthritis and one had anaphylactic
shock in response to antibiotic therapy for sepsis. Mortality
was 34.6%. The mean (± standard error) Acute Physiology
and Chronic Health Evaluation (APACHE) II [14] score was
25.3 ± 1.5, the multiple organ dysfunction syndrome (MODS)
score [15] was 7.78 ± 0.56 and Sequential Organ Failure
Assessment (SOFA) score [16] was 9.09 ± 0.59 at admission
to the ICU. All the patients who died did so before day 14. The
characteristics of the study patients are summarised in Table
1.
Surviving and nonsurviving patients with septic shock 
show different patterns of circulating T cell subsets
Counts and distributions of the main circulating T lymphocyte
subsets were systematically examined in 52 patients with sep-
tic shock at admission to the ICU and at 3, 7, 14 and 28 days
of follow up in the ICU. Furthermore, patients were classified
as survivors or nonsurvivors according to their clinical out-
come of sepsis during the four weeks of follow up. Thirty-six
healthy blood donors who were age-matched and sex-
matched (60 ± 3.4 years, 25 men and 11 women) were stud-
ied in parallel with the patients as controls of the adequacy of
the cytometric technique procedure as well as for characteri-
sation of the normal range of the T lymphocyte compartment
parameters analysed.
Both surviving and nonsurviving patients showed significantly
lower absolute CD3+ T lymphocyte numbers (surviving 740 ±
152 cells/μl, non surviving 746 ± 144 cells/μl respectively)
than controls (1394 ± 36 cells/μl) on admission and during
the first 14 days of follow up (surviving 7 and 14 days 575 ±
148 cells/μl and 1044 ± 150 cells/μl, respectively, non surviv-
ing 7 days 713 ± 70 cells/μl). In survivors, CD3+ counts had
Table 1
Clinical characteristics of the patients with septic shock at intensive care unit admission
Outcome
Controls
(n = 52)
Survivors
(n = 34)
Nonsurvivors
(n = 18)
p value
(Survivor vs nonsurvivor)
Age (years) 62.0 ± 3.4 61.0 ± 3.3 64.5 ± 4.2 0.57
Sex, n (%)* 0.11
Male 36 (69.3) 21 (61.8) 15 (83.3)
Female 16 (30.7) 13 (38.2) 3 (16.6)
Lymphocyte
(cells/μl)
2095 ± 93 1048 ± 192 1235 ± 178 0.61
Scores at admission in ICU
APACHE II 21.64 ± 1.38 29.25 ± 1.50 0.001
MODS 6.65 ± 0.54 9.57 ± 0.99 0.014
δ-MODS 2.25 ± 0.38 3.54 ± 0.73 0.169
SOFA 7.96 ± 0.67 10.64 ± 0.89 0.021
δ-SOFA 1.70 ± 0.47 2.90 ± 0.96 0.34
Pathogen types, n (%)* 0.517
Gram-positive cocci 8 (23.5) 3 (16.7)
Gram-negative bacilli 6 (17.7) 4 (22.2)
Polymicrobial disease 3 (8.8) 4 (22.2)
Unknown, non-detectable 17 (50.0) 7 (38.9)
Data are number of patients (%) or mean ± standard error of the mean.
* P values were determined by bivariate statistical analysis.
APACHE = Acute Physiology and Chronic Health Evaluation; ICU = intensive care unit; MODS = multiple organ dysfunction syndrome; SOFA = 
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significantly returned to normal by day 28 (1191 ± 172 cells/
μl). The CD3+CD4+ T cell subset was also reduced in surviv-
ing and nonsurviving patients with respect to healthy controls
at baseline and during the first week of follow up. However,
this dramatically decreased CD3+CD4+ T lymphocyte count
had normalised in survivors by day 14 (Figure 1a). On admis-
sion, CD3+CD8+ T lymphocytes were also lower in survivors
and nonsurvivors versus controls. In survivors, this T cell sub-
set showed a further drop on day 3 of follow up, followed by a
gradual recovery, although numbers failed to reach the counts
Figure 1
Kinetics of peripheral blood counts of T lymphocyte subsets in patients with septic shock during their stay in the intensive care unit Kinetics of peripheral blood counts of T lymphocyte subsets in patients with septic shock during their stay in the intensive care unit. Data presented 
as surviving patients (black tirangles) and nonsurviving patients (white triangles). The dotted line represents the mean value recorded in the healthy 
controls. All values are expressed as the mean number of cells per microlitre ± standard error of the mean. * P < 0.05 for survivors or nonsurvivors 
versus healthy controls; † P < 0.05 for survivors versus nonsurvivors; ‡ P < 0.05 for each follow up time versus baseline or admission to the intensive 
care unit.Available online http://ccforum.com/content/13/1/R26
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recorded in healthy controls. In addition, CD3+CD8+ T lym-
phocyte count in survivors was significantly diminished with
respect to nonsurvivors on day 3 (Figure 1b).
The activation stage of the CD3+CD4+ and CD3+CD8+ T
lymphocytes was determined by examining the expression of
the CD45 RA and RO isoforms. The retraction in circulating
CD3+CD4+ and CD3+CD8+ T lymphocytes observed in the
patients could be mainly explained by a decrease in the nonef-
fector CD45RA+CD45RO- subset (Figures 1g,j). Interest-
ingly, CD3+CD4+CD45RA+CD45RO- and
CD3+CD8+CD45RA+CD45RO- T lymphocytes remained
low in survivors at the end of follow up. We detected a signif-
icant decrease in CD3+CD4+CD45RA+CD45RO- T cells on
day 3 with respect to the nonsurviving patients.
CD3+CD4+CD45RA-CD45RO+ T cell counts varied over
time from a significant reduction during the first week of follow
up to elevated numbers in survivors during the last two weeks
of the study (Figures 1g,h). Finally, the analysis of effector sub-
sets, characterised by being double positive
(CD45RA+CD45RO+) [6,17,18], showed that were signifi-
cantly reduced in both CD4+ and CD8+ T lymphocyte sub-
sets at baseline, 3 and 7 days in both groups of patients
compared with controls and in survivors compared with non-
survivors at 3 days. From day 7 of follow up onwards, these
values normalised in the surviving patients (Figures 1i,l).
We also analysed the expression of CD28 and CD62L anti-
gens on CD3+CD4+ and CD3+CD8+ T lymphocytes. When
CD3+CD8+ T lymphocytes are activated, CD28 expression is
lost [19,20]. The number of circulating CD3+CD8+CD28+ T
cells was significantly and constantly reduced in patients with
septic shock compared with the healthy subjects and in survi-
vors compared with nonsurvivors during the first three days of
follow up (Figures 1e and 2). Similar behaviour was shown by
CD3+CD8+CD62L+ T cells (Figures 1f and 2). Numbers of
circulating CD3+CD8+CD28- T cells were normal in both
groups of patients (data not shown).
A prediction receptor operative curve (ROC) was then used to
estimate the value of CD3+CD8+CD28+ and
CD3+CD8+CD62L+ T cell counts for predicting death in the
patients with septic shock at admission and days 3 and 7. We
found that a cutoff value of 136 CD3+CD8+CD28+ T cells/
ml on admission to the ICU of a patient with septic shock
showed a sensitivity of 70% and 100% specificity for predict-
ing the risk of death, and the area under the ROC curve was
0.84. For the CD3+CD8+CD62L+ T cells, the cut off on
admission was 141 cells/ml, with a 60% sensitivity and 100%
specificity for predicting the risk of death and an area under
the curve of 0.75. The sensitivity and specificity of the data
obtained at days 3 and 7 were worse than those found at
admission (data not shown).
The number of circulating CD3+CD4+CD28+ T cells was
significantly lower in surviving and nonsurviving patients with
septic shock compared with healthy controls on admission
and on day 3 of follow-up (Figure 1c). In survivors, this was fol-
lowed by a gradual recovery of CD3+CD4+CD28+ T cell
numbers during the course of follow up. CD3+CD4+CD62L+
T cells showed a similar pattern of behaviour (Figure 1d). In the
parallel study performed in healthy blood donors (at 0 and 28
days of the follow up), no significant variations in the absolute
counts and distribution of the different subsets of T cells ana-
lysed were detected.
Discussion
In this study, we show that surviving and nonsurviving patients
with septic shock have different patterns of involvement in cir-
culating T lymphocyte compartment. A drop in circulating
CD3+CD4+ and CD3+CD8+ T cells has been described in
patients with severe sepsis or septic shock at admission to the
ICU [8-12]. In our kinetic study, we also observed that this T
lymphopenia persists during the first week of follow up and is
independent of the outcome. Moreover, by the end of the sec-
ond week of follow up, the absolute number of circulating
CD3+CD4+ T cells had clearly normalised. In contrast, after
four weeks of follow up, there was still no return to normal cir-
culating numbers of CD3+CD8+ T cells.
In a mouse sepsis model of caecal ligation and puncture, the
depletion of CD3+CD8+ T and natural killer cells was associ-
ated with a survival benefit with decreased blood bacterial
concentrations, improved physiological function and an atten-
uated proinflammatory response [21]. It has been reported
that mice infected with Plasmodium berghei develop a syn-
drome similar to septic shock and the depletion of
CD3+CD8+ T cells also significantly ameliorates the compli-
cations that induce shock [22]. In addition, in patients with
trauma and multiple organ failure, nonsurvivors showed
CD3+CD8+ T cell numbers that were two-fold those
recorded in survivors [23]. In agreement with these experimen-
tal and clinical findings, we observed significantly lower
CD3+CD8+ T cell counts in survivors compared with nonsur-
vivors on day three of follow up. Thus, diminished circulating
CD3+CD8+T cells might have a protective pathogenic role in
the outcome of septic shock.
CD45 is a phosphatase that is essential in T cell development
and antigen receptor signalling [24]. The expression patterns
of the RA and RO isoforms of CD45 by T lymphocytes serve
to identify subsets associated with different stages of T cell
activation [6]. When noneffector CD45RA+CD45RO- T lym-
phocytes are activated by inflammatory agents, such as bacte-
rial infection, CD45RO is up-regulated and CD45RA down-
regulated [6]. Thus, our patients showed a persistent reduc-
tion in circulating noneffector CD4+CD45RA+ CD45RO-
and CD8+CD45RA+ CD45RO- T cells. In contrast, numbers
of CD8+CD45RA-CD45RO+ T cells remained normal andCritical Care    Vol 13 No 1    Monserrat et al.
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CD4+CD45RA-CD45RO+ T cell counts initially fell yet had
returned to normal by the second week of follow up in surviv-
ing patients. An increased percentage of CD3+ cells express-
ing CD45RO has been reported in patients with sepsis [25].
Our findings could be the consequence of abnormal polyclo-
nal activation of circulating T lymphocytes. It has been pro-
posed that the switch of T cells from a CD45RA+CD45RO-
to a CD45RA-CD45RO+ phenotype may have a functional
effect in halting the sustained immune response in an effort to
avoid tissue injury [6]. Thus, it is possible to suggest that the
expansion of CD4+CD45RA-CD45RO+ T lymphocytes
observed here during the follow up of surviving patients might
be considered a compensatory anti-inflammatory mechanism
that develops in these patients with septic shock.
CD28 is a costimulatory molecule that plays a key role in reg-
ulating the activation and survival of T lymphocytes [26]. Acti-
vation of CD3+CD8+ T lymphocytes has been related to the
Figure 2
Flow cytometry data analysis of the CD28 and CD62L surface expression in CD3+CD8+ T lymphocytes from peripheral blood of septic shock  patients Flow cytometry data analysis of the CD28 and CD62L surface expression in CD3+CD8+ T lymphocytes from peripheral blood of septic shock 
patients. Panels show CD28 and CD62L expression by CD3+CD8+ gated (Region = R) lymphocytes from peripheral blood of a representative (a) 
healthy control, (b) nonsurvivor and (c) survivor septic shock patient at the moment of admission to the intensive care unit.Available online http://ccforum.com/content/13/1/R26
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loss of CD28 expression [19,20]. In effect, it has been
reported that patients with severe sepsis showed a significant
reduction in T lymphocyte CD28 expression [27]. Our data
indicate diminished circulating CD3+CD8+CD28+ T cell
numbers in patients with septic shock with respect to healthy
subjects on admission to the ICU and at least during the first
28 days of follow up. Interestingly, a reduced
CD3+CD8+CD28+ T cell count during the first three days of
admission to the ICU was of prognostic value for predicting
the survival of a patient. Conversely, an elevated number of cir-
culating CD3+CD8+CD28+ T cells was associated with a
worse prognosis for the patient. Recently, it has been reported
that the stimulation of CD28 by a monoclonal antibody in
healthy volunteers is followed by severe multiple cytokine-
release syndrome [28]. Our results support a relevant role for
CD3+CD8+CD28+ T cells in the pathogenesis of septic
shock. Future studies should address the potential clinical rel-
evance of this cell variable.
The migration of circulating T lymphocytes to peripheral lymph
nodes depends on the expression of the CD62L homing
receptor [29]. We found here that the down-regulation of L-
selectin expression on CD3+CD8+ cells in patients with sep-
tic shock was associated with a better outcome. Hence, the
rapid migration of CD8+ T cells to peripheral lymph nodes may
be a mechanism contributing to patient survival.
Our T lymphocyte phenotype data show a time difference, or
shift, in the recirculation of T lymphocytes between patients
who survive septic shock and those who do not. Taken
together and analysing the phenotype of the circulating T cells
according to the activation criteria (CD45RA+ and
CD45RO+) related to CD28 (activation and co-stimulation)
and CD62L (activation and migration) expression point to a
slower migration of naive and effector cells in nonsurviving
patients. This different T lymphocyte kinetics would mean a
delayed tissue response that could determine the failure of the
immune system and the fatal prognosis of the patient. In par-
ticular, the delay in the disappearance of CD45RA+,
CD45RA+CD45RO+, CD28+, CD62L+, T CD4+ and CD8+
lymphocytes observed between days 3 and 7 of follow up in
the nonsurvivors appears to be crucial to the final outcome.
Accordingly, in surviving patients, effector cells would migrate
more rapidly to tissues and this would in turn trigger the quick
action of the immune system in combating the infection and
thus determine the survival of the patient. It is known that cel-
lular immune responses play a critical role in the defense
against viral infections and strong T-cell responses have been
reported in patients who clear infection [30]. If the immune
response is late or less efficient against microorganism viral
epitopes, the outcome of the disease worsens [30-33].
Not surprisingly, the survivor group had lower APACHE II,
MODS and SOFA scores than nonsurvivors. An increasing
APACHE II score reflects an increasing severity of illness and
escalating risk of hospital death for multidiagnostic ICU patient
groups. However, an APACHE II score cannot be directly
equated with a specific risk of lower mortality than the same
score for a patients with septic shock [34]. In this group of
patients, we found that a cut-off value of 136 cells/ml for
CD3+CD8+CD28+ T cells and 141 cells/ml for
CD3+CD8+CD62L+ T cells on ICU admission showed high
specificity for predicting the risk of death. However, it is known
that the positive predictive value for APACHE II for the valida-
tion study population was only 69.6% and the negative predic-
tive value was 87.9% [35]. Moreover, SOFA, MODS and
APACHE II scores require at least 24 hours of monitoring to
be performed and lymphocyte phenotyping can be performed
in a short time (approximately 2 hours). It is not possible to
replace clinical score in septic shock patients by immunologi-
cal markers. However, these analytical parameters may help to
make clinical decisions in these patients and to establish new
potential therapeutic targets. Future studies will need to study
in more depth the mechanisms involved in the severe abnor-
mality found on the T cell compartment in patients with septic
shock.
Conclusions
Septic shock patients show a severe redistribution of circulat-
ing T lymphocyte subsets. We found that CD62L and CD28
expression on circulating T cells at ICU admission are good
markers to predict the outcome of shock septic patients. T
lymphocyte phenotype data show a time difference in the recir-
culation of T cells between survivors and nonsurvivors that
might provoke a delayed tissue response of the immune sys-
tem.
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